OBJECTIVE: In the last few years some of the therapeutical approaches for Duchenne muscular dystrophy (DMD) are specifically targeting distinct groups of mutations, such as deletions eligible for skipping of individual exons. The aim of this observational study was to establish whether patients with distinct groups of mutations have different profiles of changes on the 6 minute walk test (6MWT) over a 12 month period. METHODS: The 6MWT was performed in 191 ambulant DMD boys at baseline and 12 months later. The results were analysed using a test for heterogeneity in order to establish possible differences among different types of mutations (deletions, duplications, point mutations) and among subgroups of deletions eligible to skip...
The 6 minute walk test has been recently chosen as the primary outcome measure in international mult...
IntroductionAn international clinical trial enrolled 174 ambulatory males ≥5 years old with nonsense...
Novel emerging therapies for Duchenne muscular dystrophy (DMD), such as antisense oligomer (AO) medi...
Objective In the last few years some of the therapeutical approaches for Duchenne muscular dystro...
<div><p>Objective</p><p>In the last few years some of the therapeutical approaches for Duchenne musc...
In the last few years some of the therapeutical approaches for Duchenne muscular dystrophy (DMD) are...
Objective: In the last few years some of the therapeutical approaches for Duchenne muscular dystroph...
INTRODUCTION: The aim of this international collaborative effort was to report 36-month longitudina...
Objective:To correlate time to loss of ambulation (LoA) and different truncating DMD gene mutations ...
INTRODUCTION: Duchenne muscular dystrophy (DMD) subjects ≥5 years with nonsense mutations were follo...
An international clinical trial enrolled 174 ambulatory males ≥5 years old with nonsense mutation Du...
IntroductionDuchenne muscular dystrophy (DMD) subjects ≥5 years with nonsense mutations were followe...
The 6 minute walk test has been recently chosen as the primary outcome measure in international mult...
<div><p>The 6 minute walk test has been recently chosen as the primary outcome measure in internatio...
The 6 minute walk test has been recently chosen as the primary outcome measure in international mult...
The 6 minute walk test has been recently chosen as the primary outcome measure in international mult...
IntroductionAn international clinical trial enrolled 174 ambulatory males ≥5 years old with nonsense...
Novel emerging therapies for Duchenne muscular dystrophy (DMD), such as antisense oligomer (AO) medi...
Objective In the last few years some of the therapeutical approaches for Duchenne muscular dystro...
<div><p>Objective</p><p>In the last few years some of the therapeutical approaches for Duchenne musc...
In the last few years some of the therapeutical approaches for Duchenne muscular dystrophy (DMD) are...
Objective: In the last few years some of the therapeutical approaches for Duchenne muscular dystroph...
INTRODUCTION: The aim of this international collaborative effort was to report 36-month longitudina...
Objective:To correlate time to loss of ambulation (LoA) and different truncating DMD gene mutations ...
INTRODUCTION: Duchenne muscular dystrophy (DMD) subjects ≥5 years with nonsense mutations were follo...
An international clinical trial enrolled 174 ambulatory males ≥5 years old with nonsense mutation Du...
IntroductionDuchenne muscular dystrophy (DMD) subjects ≥5 years with nonsense mutations were followe...
The 6 minute walk test has been recently chosen as the primary outcome measure in international mult...
<div><p>The 6 minute walk test has been recently chosen as the primary outcome measure in internatio...
The 6 minute walk test has been recently chosen as the primary outcome measure in international mult...
The 6 minute walk test has been recently chosen as the primary outcome measure in international mult...
IntroductionAn international clinical trial enrolled 174 ambulatory males ≥5 years old with nonsense...
Novel emerging therapies for Duchenne muscular dystrophy (DMD), such as antisense oligomer (AO) medi...